Barinthus Biotherapeutics plc (BRNS)

Market Cap	97.00M
Revenue (ttm)	802,000
Net Income (ttm)	-73.35M
Shares Out	38.64M
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,441
Open	2.671
Previous Close	2.670
Day's Range	2.510 - 2.671
52-Week Range	1.640 - 5.100
Beta	-0.51
Analysts	Strong Buy
Price Target	8.00 (+218.73%)
Earnings Date	May 10, 2024

About BRNS

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human p...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2021
• Employees: 130
• Stock Exchange: NASDAQ
• Ticker Symbol: BRNS

Analyst Forecast

According to one analyst, the rating for BRNS stock is "Strong Buy" and the 12-month stock price forecast is $8.0.

Price Target

$8.0

(218.73% upside)

Analyst Consensus: Strong Buy